NEW YORK (GenomeWeb) – Molecular diagnostics firm IntegraGen today announced a distribution deal with Genoma to commercialize IntegraGen's Arisk autism spectrum disorder genetic risk assessment test outside the US.
Financial and other terms of the deal were not disclosed.
IntegraGen CEO Bernard Courtieu said in a statement that the test will allow physicians to refer and diagnose children with ASD and to start treatments when they are most effective, before the age of three. Genoma, an Italian molecular genetics laboratory, plans to offer the test to all geographies where it operates, the firms said. It will be used to test children with suspected developmental disorder and to test children with older siblings previously diagnosed with ASD.
Genoma will also provide genetic consulting services to the parents, as well as all diagnostic services to the children and their parents, IntegraGen said.
IntegraGen is based in Evry, France. Courtieu said that with children being diagnosed with autism when it is too late to implement early interventional treatment options, "the utilization of this test will contribute to earlier clinical diagnosis and improve the care of children with" ASD.